Genmab A/S, of Copenhagen, reported that for the fourth quarter of 2013 net sales of Arzerra (ofatumumab), an anti-CD20 antibody indicated for chronic lymphocyte leukemia refractory to fludarabine and alemtuzumab, and marketed by its partner Glaxosmithline plc, was approximately DKK168 million (US$30.5 million). Under terms of its collaboration with GSK, the company expects to receive a royalty payment on these sales of approximately DKK34 million. Full year 2013 net sales of Arzerra totaled approximately DKK658 million (US$119 million) worldwide, resulting in total royalty income of approximately DKK131 million.